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Abstract Adverse events triggered by non-steroidal anti-
inXammatory drugs (NSAIDs) are among the most com-
mon drug-related intolerance reactions in medicine; they
are possibly related to inhibition of cyclooxygenase-1. Cox-
ibs, preferentially inhibiting cyclooxygenase-2, may there-
fore represent safe alternatives in patients with NSAID
intolerance. We reviewed the literature in a systematic and
structured manner to identify and evaluate studies on the
tolerance of coxibs in patients with NSAID intolerance. We
searched MEDLINE (1966–2006), the COCHRANE
LIBRARY (4th Issue 2006) and EMBASE (1966–2006) up
to December 9, 2006, and analysed all publications
included using a predeWned evaluation sheet. Symptoms
and severity of adverse events to coxibs were analysed
based on all articles comprising such information. Subse-
quently, the probability for adverse events triggered by cox-
ibs was determined on analyses of double-blind prospective
trials only. Among 3,304 patients with NSAID intolerance,
119 adverse events occurred under coxib medication. All
adverse events, except two, have been allergic/urticarial in
nature; none was lethal, but two were graded as life-threat-
ening (grade 4). The two non-allergic adverse events were
described as a grade 1 upper respiratory tract haemorrhage,
and a grade 1 gastrointestinal symptom, respectively. In 13
double-blind prospective studies comprising a total of 591
patients with NSAID intolerance, only 13 adverse reactions
to coxib provocations were observed. The triggering coxibs
were rofecoxib (2/286), celecoxib (6/208), etoricoxib (4/
56), and valdecoxib (1/41). This review documents the
good tolerability of coxibs in patients with NSAID intoler-
ance, for whom access to this class of drugs for short-term
treatment of pain and inXammation is advantageous.
Keywords Non-steroidal anti-inXammatory drugs · 
Intolerance · Urticaria · Adverse drug reaction · Coxibs
Introduction
Non-steroidal anti-inXammatory drugs (NSAIDs) are the
most commonly used therapeutics in the outpatient man-
agement of pain and inXammation in a wide spectrum of
diseases. Their primary mode of action is the blockade of
prostaglandin synthesis by cyclooxygenases (COX): Con-
stitutively expressed COX-1 is involved in fundamental
mechanisms of homeostasis, whereas the inducible COX-2
mediates inXammation. Therapeutic eVects of NSAIDs are
primarily related to their ability to inhibit COX-2, whereas
some of their most frequent adverse eVects may be caused
by COX-1 inhibition (Fig. 1). In contrast to most “classic”
NSAIDs which block both isoforms, the so-called coxibs
preferentially inhibit COX-2. This may result in better tol-
erability, namely reduction of gastrointestinal side eVects
[29, 85].
Respiratory and cutaneous adverse events triggered by
NSAIDs are among the most common drug-related intoler-
ance reactions in medicine. Typically, these manifest as
asthma attacks or urticaria. Pathogenesis of these symptoms
seems to be related to COX-1 inhibition [76]. Therefore,
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the hypothesis was put forward that coxibs may safely be
used in patients with known NSAID intolerance. However,
serious intolerance reactions to coxibs have also been
observed, thus cautioning too euphoric expectations [71].
We therefore reviewed the relevant literature in a system-
atic and structured approach for evidence of coxib tolerance
in patients with NSAID intolerance.
Methods
Search strategy
We searched MEDLINE (1966–2006), the COCHRANE
LIBRARY (4th Issue 2006) and EMBASE (1966–2006) up
to December 9, 2006. The following search terms were
used: rofecoxib OR celecoxib OR valdecoxib OR parec-
oxib OR etoricoxib, combined with hypersensitivity OR
intolerance. Those coxibs used in veterinary medicine (der-
acoxib, tiracoxib and cimicoxib) were not included in the
literature search. No language or publication restriction was
predeWned. All publications reporting individual patients
with NSAID intolerance and subsequent exposure to a
COX-2 Inhibitor were identiWed and the reference lists of
these articles were hand-searched for further publications.
If articles could not be retrieved in full text, a copy was
requested from the corresponding author and/or journal edi-
tor.
Inclusion criteria
Each publication was appraised for inclusion in a stepwise
approach (Fig. 2). Only publications describing individual
patients and providing a rational medication scheme as well
as a suYciently speciWc outcome report were included in
this review. In a Wrst step, evaluation focused on clinical
symptoms and severity of adverse events in patients with
NSAID intolerance. Therefore, all articles on this topic
were included for this analysis. Subsequently, the probabil-
ity for adverse events was analysed based exclusively on
publications of double-blind prospective trials.
Data extraction and synthesis
All articles were analysed using a predeWned evaluation
sheet. Uncertainties were resolved by consensus decisions
among the investigators. Data synthesis was qualitative and
descriptive. The Common Terminology Criteria for
Adverse Events version 3.0 (CTCAE) was used to catego-
rize adverse events.
Results
We identiWed 230 publications on coxibs and/or NSAID
intolerance. Hundred and forty-six references not focusing on
individual patients with NSAID intolerance were excluded.
Unclear medication schemes or outcome reports led to exclu-
sion of two articles. Eighty-four publications were evaluated
for severity and type of adverse reactions to coxibs. Thirteen
publications on double-blind studies were used to determine
the probability of adverse reactions to coxibs.
Severity and type of adverse events to coxibs
A total of 119 adverse events among 3,304 patients exposed
to coxibs were identiWed [1–18, 20–24, 26–28, 30–35, 37–
58, 60–75, 77–84, 86–89]. Adverse events were described
Fig. 1 Cyclooxygenase iso-
forms. Non-steroidal anti-
inXammatory drugs (NSAIDs) 
block prostaglandin synthesis by 
cyclooxygenases (COX). Two 
isoforms exist of this enzyme: 
constitutively expressed COX-1 
is involved in fundamental 
mechanisms of homeostasis, 
whereas the inducible isoform 
COX-2 mediates inXammationArch Dermatol Res (2007) 299:169–175 171
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for rofecoxib (48/1,732), celecoxib (59/1,148), etoricoxib
(10/328), and valdecoxib (2/69), but not parecoxib (0/27)
(Table 1). All adverse events, except two, have been allergic/
urticarial in nature, and none was lethal. One adverse event
after administration of rofecoxib and one after celecoxib
were reported as life-threatening (grade 4). The two non-
Fig. 2 Flow chart documenting 
the handling data (NSAID non-
steroidal anti-inXammatory 
drugs)
Table 1 Mode and severity of adverse event (CTCAE common terminology criteria for adverse events)
Numbers and grade of adverse events (in parentheses) are indicated
Patients Events 
(total)
Urticaria 
(grade)
Allergic 
reactions 
(grade) 
Allergic 
rhinitis 
(grade)
Airway 
obstruction 
(grade)
Gastroin-testinal 
symtpms (grade)
Pruritus 
(grade)
Hemorrhage, 
upper respiratory 
(grade)
Rofecoxib 1,732 48 9 (1)
8 (2)
1 (3)
25 (3)
1 (4)
1 (2) 2 (1) 0 0 1 (1)
Celecoxib 1,148 59 19 (1)
1 (2)
1 (2)
33 (3)
1 (4)
0 1 (1) 0 3 (2) 0
Etoricoxib 328 10 3 (1)
5 (2)
1 (3) 0 0 1 (1) 0 0
Valdecoxib 69 2 1 (1)
1 (2)
00 0 0 0 0
P a r e c o x i b 2 7 0 000 0 0 0 0
Total 3,304 119 48 62 1 3 1 3 1172 Arch Dermatol Res (2007) 299:169–175
123
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allergic adverse events were described as a grade 1 upper
respiratory tract haemorrhage, namely blood in nasal dis-
charge after provocation with rofecoxib, and a grade 1 gas-
trointestinal symptom, namely nausea and abdominal pain.
Evaluation of double-blind studies
We identiWed 13 double-blind studies evaluating tolerabil-
ity of coxibs in a total of 591 NSAID intolerant patients
(Table 2). The coxibs tested in the context of these studies
were rofecoxib (n = 286), celecoxib (n = 208), etoricoxib
(n = 56) and valdecoxib (n = 41). Among the 591 patients
described, 13 exhibited adverse reactions upon provocation
with a coxib. The triggering coxibs were rofecoxib (2/286),
celecoxib (6/208), etoricoxib (4/56), and valdecoxib (1/41)
[13, 28, 48, 60, 69, 74, 75, 77, 78, 83, 84, 87, 88]. One of
these reactions was clearly non-allergic, this one being the
above-mentioned individual with grade 1 upper respiratory
tract haemorrhage.
Discussion
This systematic review documents the low probability of
allergic/pseudo-allergic reactions induced by coxibs in
patients with NSAID intolerance. To our knowledge, this is
the Wrst comprehensive analysis of data published on this
topic. We have searched all three major medical databases
available, namely MEDLINE, COCHRANE LIBRARY,
and EMBASE using very broad and general search terms.
Following identiWcation of relevant publications, these
were evaluated by means of a pre-deWned evaluation form.
The data available are described in the form of a structured
review [19].
NSAIDs are among the most commonly prescribed ther-
apeutics in the world. Although generally considered safe,
their wide and frequent use results in these drugs being
among the most common causes of drug-related intolerance
reactions. This may at least in part be due to their non-
selective inhibition of both cyclooxygenase isoforms. In
line with this hypothesis, NSAIDs characterized by pro-
nounced COX-1 inhibition bear a high risk to trigger
asthma attacks in patients with aspirin-sensitive asthma
bronchiale, whereas preferentially COX-2 inhibiting NSA-
IDS are better tolerated by these patients [36]. Our analysis
of published studies on this issue further supports this
notion, as only 13 of 591 NSAID-intolerant patients
showed adverse reactions upon provocation with coxibs in
double-blind clinical studies; all of these were grade 3 or
milder. Still, relatively selective COX-2 inhibitors have
been identiWed as triggers of serious intolerance reactions
[71]. This implies that our current understanding of
NSAID-triggered intolerance is still imperfect, and its path-
ogenesis cannot be reduced to cyclooxygenase-mediated
eVects alone, but needs to take into account clinically rele-
vant additional NSAID-mediated eVects such as secretion
of leukotrienes from mast cells and other leukocytes.
It has been suggested that coxibs may confer an elevated
risk for acute myocardial infarction and sudden cardiac
death, namely after long-term therapy [25]. As a reaction,
several coxibs are no longer available despite a recommen-
dation by the participants of an expert meeting organized
by the Food and Drug Administration to grant further pre-
scription of rofecoxib, celecoxib and valdecoxib in the US
[59]. On the other hand, substantial evidence described here
points towards a good tolerability of coxibs in patients with
NSAID intolerance. Given the wide use of NSAIDs in the
short-term treatment of trivial signs and symptoms, the
availability of coxibs for these indications would be advan-
tageous for this relevant subpopulation of patients, since
this type of application is unlikely to increase cardiac risk.
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